269 related articles for article (PubMed ID: 18678301)
1. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.
Terra SG; Francone OL; Contant CF; Gao X; Lewin AJ; Nguyen TT
Am J Cardiol; 2008 Aug; 102(4):434-9. PubMed ID: 18678301
[TBL] [Abstract][Full Text] [Related]
2. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR; Sullivan DR; Ehnholm C; Whiting M; Zannino D; Simes RJ; Keech AC; Barter PJ;
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):950-5. PubMed ID: 19325138
[TBL] [Abstract][Full Text] [Related]
3. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.
Duez H; Lefebvre B; Poulain P; Torra IP; Percevault F; Luc G; Peters JM; Gonzalez FJ; Gineste R; Helleboid S; Dzavik V; Fruchart JC; Fiévet C; Lefebvre P; Staels B
Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):585-91. PubMed ID: 15618549
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
5. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Mohiuddin SM; Pepine CJ; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Am Heart J; 2009 Jan; 157(1):195-203. PubMed ID: 19081418
[TBL] [Abstract][Full Text] [Related]
7. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes.
Albert SG; Oiknine RF; Parseghian S; Mooradian AD; Haas MJ; McPherson T
Diabetes Care; 2007 Nov; 30(11):2800-3. PubMed ID: 17682119
[TBL] [Abstract][Full Text] [Related]
8. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
[TBL] [Abstract][Full Text] [Related]
10. A selective peroxisome proliferator-activated receptor alpha agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys.
Wagner JD; Shadoan MK; Zhang L; Ward GM; Royer LJ; Kavanagh K; Francone OL; Auerbach BJ; Harwood HJ
J Pharmacol Exp Ther; 2010 Jun; 333(3):844-53. PubMed ID: 20190014
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
[TBL] [Abstract][Full Text] [Related]
12. Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.
Roglans N; Bellido A; Rodríguez C; Cabrero A; Novell F; Ros E; Zambón D; Laguna JC
Clin Pharmacol Ther; 2002 Dec; 72(6):692-701. PubMed ID: 12496750
[TBL] [Abstract][Full Text] [Related]
13. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Maciejewski S; Hilleman D
Pharmacotherapy; 2008 May; 28(5):570-5. PubMed ID: 18447655
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Goldberg AC; Bays HE; Ballantyne CM; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
Am J Cardiol; 2009 Feb; 103(4):515-22. PubMed ID: 19195513
[TBL] [Abstract][Full Text] [Related]
16. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Nissen SE; Nicholls SJ; Wolski K; Howey DC; McErlean E; Wang MD; Gomez EV; Russo JM
JAMA; 2007 Mar; 297(12):1362-73. PubMed ID: 17384435
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate: treatment of hyperlipidemia and beyond.
Rosenson RS
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1319-30. PubMed ID: 19018684
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
[TBL] [Abstract][Full Text] [Related]
20. Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.
Yang LP; Keating GM
Am J Cardiovasc Drugs; 2009; 9(6):401-9. PubMed ID: 19929038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
